Acceleron Pharma (XLRN) Prices 4.864M Share Common Offering at $92.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- Houthi strike on Saudi airport kills 12, worst attack on kingdom in a decade
- US consumer sentiment near record low as frustration over economy mounts
- 8.0 Mag. Earthquake 14 Km Sw Of Pitaloza Arriba Panama - USGS
- Strong Panama quake shakes nation, but avoids major destruction
- Nio stock jumps after Goldman Sachs upgrade to buy
Acceleron Announces Pricing of Public Offering of Common Stock
June 30, 2020 6:48 PM EDTCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that it has priced an underwritten public offering of 4,864,864 shares of common stock at a price to the public of $92.50 per share for gross proceeds of $450.0 million. In connection with this offering, Acceleron has granted the underwriters a 30-day option to purchase up to an additional 729,729 shares of common stock.
J.P. Morgan, SVB Leerink and Cowen are acting as joint... More



